EMA Authorised: Jascayd (nerandomilast) — Boehringer Ingelheim International GmbH

View source ↗

Summary

Jascayd (nerandomilast) has been authorised in the EU for idiopathic pulmonary fibrosis by Boehringer Ingelheim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• JASCAYD (NERANDOMILAST)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis. MAH: Boehringer Ingelheim International GmbH. Decision date: 15/07/2026